Primary follicular lymphoma of the fallopian tube found incidentally in a patient treated for endometrial carcinoma: a case report

We report a rare case of primary lymphoma of fallopian tube in a 68-year-old woman who underwent total hysterectomy and bilateral salpingo-oophorectomy for endometrial carcinoma. The specimen showed a well-differentiated endometrioid adenocarcinoma with superficial myometrial invasion. The left fallopian tube revealed a 1 cm nodule that histologically showed diffuse lymphoid follicles consisting of small cleaved lymphocytes and occasional larger cells. The cells were immunopositive for CD20, BCL-2, and BCL-6 but negative for CD3 and CD43. Polymerase chain reaction confirmed a monoclonal B-cell population. Fluorescence in-situ hybridization revealed at (14, 18) translocation. The patient had absent lymphadenopathy and negative CT scan of chest, abdomen, and pelvis. The findings were consistent with a primary low grade follicular lymphoma of fallopian tube. She did not receive chemotherapy and remained disease free for 13 months after surgery. Our case suggests that primary lymphoma of fallopian tube may be associated with a favorable prognosis

Ensuring Shariah compliance in Islamic financial institutions as an essential interest of shareholders

Islamic financial institutions are committed to conduct their business in compliance with the rules of Islamic Shariah. In order to ensure their Shariah compliance and win the trust of their shareholders and other stakeholders they usually implement a special type of corporate governance called ‘Shariah corporate governance’. The key feature of this governance policy is the appointment of a Shariah supervisory board in the internal structure of the institution. IFIs around the world operate under three main regulatory and supervisory systems of Shariah corporate governance. Some countries apply a centralised system, while others implement a decentralised system, yet others completely lack this regulation and supervision. Nevertheless, with all the measures taken by the IFIs and jurisdictions, Shariah corporate governance still encounters some problems that might jeopardise its effectiveness in achieving its objective of ensuring proper Shariah compliance in IFIs. Therefore, this thesis argues that shareholders of IFIs – as the third main pillar of corporate governance alongside the institution and the authority – need to play their role as stewards and actively engage with their investee IFIs. It is believed that Shariah compliance is an important interest to these shareholders, and therefore they are expected to defend this interest. It is essential that shareholders of IFIs are equipped with specific rights in Shariah corporate governance especially toward the SSB and the IFI’s Shariah compliance in order to engage more with their institutions. Also, their activism needs to be encouraged and guided with some regulatory rules. In this context it is important for shareholders, especially institutional shareholders, to utilise their power and use all possible means to ensure the delivery of a proper Islamic business by the institutions they invest with. There is no doubt that shareholders might face some obstacles to their activism, however this should not stop them from practising their stewardship role

A Study of Business Administration College Students' Decision-Making Skills at Kuwait University

Abstract This study aims to investigate the Decision-Makin

Metastatic Malignant Melanoma Presenting as an Appendiceal Mucocele

Melanoma metastatic to the appendix is extremely rare. Here we describe a case of a 31-year-old female from Bolivia with a remote history of metastatic malignant melanoma first diagnosed as a cutaneous malignant melanoma ten years prior to this presentation. The patient was being followed for a mucocele which on resection was found to be metastatic melanoma. “Mucocele” is a generic diagnosis that warrants further characterization and treatment

Towards an open ambidextrous system : how organizations manage exploration and exploitation in open innovation environments

This research examines the telecommunication industry and uses it as an example in order to present a general model of how ambidexterity is carried out in the context of open innovation. This emerging approach to ambidexterity has been particularly evident in the telecommunication industry where exploration and exploitation activities are established on information technology structures. Ambidexterity is the idea that successful firms simultaneously explore new ideas while exploiting existing ones in order to sustain profitability, especially in dynamic environments. Few studies have discussed ambidexterity that is carried out in contexts of open innovation. For this reason, this doctoral thesis addresses this gap in our understanding of ambidexterity, and contributes to it by examining the question: "How do ambidextrous organizations carry out exploration and exploitation in open innovation environments?" A new form of ambidexterity has been identified in this study; it is an open ambidextrous system. It exists in a particularly transparent form around organizations whose innovation activities are focused on information technology infrastructure, specifically networking technologies, as has been evident in the telecommunication industry. This presents important implications for the management information systems (MIS) literature. Open ambidextrous systems are established by organizations when they manage exploration and exploitation in open innovation environments. From that understanding ambidexterity has been identified as open. This offers important insight for the ambidexterity and open innovation literatures. As a result, organizations that adopt an open ambidextrous system are recognized as performing open exploration and open exploitation, where the two activities are perceived as two complementing systems identified as the open exploration system, and the open exploitation system. Therefore, this research combines insights from the ambidexterity, open innovation, and management information systems literatures, and contributes to them by offering a new and alternative view to ambidexterity that is based on the open innovation notion

Multi-Mobile Computing

With mobile systems evermore ubiquitous, individual users often own multiple mobile systems and groups of users often have many mobile systems at their disposal. As a result, there is a growing demand for multi-mobile computing, the ability to combine the functionality of multiple mobile systems into a more capable one. However, there are several key challenges. First, mobile systems are highly heterogeneous with different software and hardware, each with their own interfaces and data formats. Second, there are no effective ways to allow users to easily and dynamically compose together multiple mobile systems for the quick interactions that typically take place with mobile systems. Finally, there is a lack of system infrastructure to allow existing apps to make use of multiple mobile systems, or to enable developers to write new multi-mobile aware apps. My thesis is that higher-level abstractions of mobile operating systems can be reused to combine heterogeneous mobile systems into a more capable one and enable existing and new apps to provide new functionality across multiple mobile systems. First, we present M2, a system for multi-mobile computing that enables existing unmodified mobile apps to share and combine multiple devices, including cameras, displays, speakers, microphones, sensors, GPS, and input. To support heterogeneous devices, M2 introduces a new data-centric approach that leverages higher-level device abstractions and hardware acceleration to efficiently share device data, not API calls. M2 introduces device transformation, a new technique to mix and match heterogeneous devices, enabling, for example, existing apps to leverage a single larger display fused from multiple displays for better viewing, or use a Nintendo Wii-like gaming experience by translating accelerometer to touchscreen input. We have implemented M2 and show that it operates across heterogeneous systems, including multiple versions of Android and iOS, and can run existing apps across mobile systems with modest overhead and qualitative performance indistinguishable from using local device hardware. Second, we present Tap, a framework that leverages M2’s data-centric architecture to make it easy for users to dynamically compose collections of mobile systems and developers to write new multi-mobile apps that make use of those impromptu collections. Tap allows users to simply tap systems together to compose them into a collection without the need for users to register or connect to any cloud infrastructure. Tap makes it possible for apps to use existing mobile platform APIs across multiple mobile systems by virtualizing data sources so that local and remote data sources can be combined together upon tapping. Virtualized data sources can be hardware or software features, including media, clipboard, calendar events, and devices such as cameras and microphones. Leveraging existing mobile platform APIs make it easy for developers to write apps that use hard- ware and software features across dynamically composed collections of mobile systems. We have implemented Tap and show that it provides good usability for dynamically composing multiple mobile systems and good performance for sharing hardware devices and software features across multiple mobile systems. Finally, using M2 and Tap, we present various apps that show how existing apps can provide useful functionality across multiple mobile systems and how new apps can be easily developed to provide new multi-mobile functionality. Examples include panoramic video recording using cameras from multiple mobile systems, surround sound music player app that configures itself based on automatically detecting the location of multiple mobile systems, and an added feature to the Snapchat app that allows multiple users to share a live Snap, using their own cameras and filters. Our user studies with these apps show that multi-mobile computing offers a richer and more enhanced experience for users and a much simpler development effort for developers

Obinutuzumab in hematologic malignancies: Lessons learned to date

AbstractThe routine use of anti-CD20 monoclonal antibodies (mAbs) has improved patient outcomes in CD20-positive non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Despite the clinical success achieved with rituximab, relapses are still common with further improvements in anti-CD20 mAb efficacy required. Many novel anti-CD20 antibodies are in development, but obinutuzumab is currently the only type II glycoengineered anti-CD20 mAb in clinical testing.Obinutuzumab has increased antibody-dependent cell-mediated cytotoxicity, reduced complement-dependent cytotoxicity and enhanced direct non-apoptotic cell death. In preclinical models, obinutuzumab induced superior tumor remission compared with rituximab at the equivalent dose levels, and was active in rituximab-refractory tumors. Obinutuzumab exhibits encouraging efficacy as monotherapy in NHL, and combined with chemotherapy in relapsed/refractory NHL and treatment-naïve symptomatic CLL. In a recent randomized, phase III trial in patients with untreated comorbid CLL, overall response rate was significantly greater (78% vs. 65%, P<0.0001) and median progression-free survival was significantly prolonged (26.7 vs. 15.2months, P<0.0001) for obinutuzumab plus chlorambucil vs. rituximab plus chlorambucil.Obinutuzumab is a type II anti-CD20 antibody that utilizes distinct mechanisms of action relative to type I antibodies like rituximab and has led to significant clinical improvement over rituximab in a phase III trial in CLL. Further trials are ongoing to determine whether such improvements in outcome will be seen in CD20-positive B-cell malignancies

Pre-Clinical Evaluation of a 213Bi-Labeled 2556 Antibody to HIV-1 gp41 Glycoprotein in HIV-1 Mouse Models as a Reagent for HIV Eradication

Any strategy for curing HIV infection must include a method to eliminate viral-infected cells. Based on our earlier proof-of-principle results targeting HIV-1 infected cells with radiolabeled antibody (mAb) to gp41 viral antigen, we embarked on identifying a suitable candidate mAb for preclinical development.Among the several human mAbs to gp41 tested, mAb 2556 was found to have high affinity, reactivity with multimeric forms of gp41 present on both the surface of virus particles and cells expressing HIV-1 Env, and recognition of a highly conserved epitope of gp41 shared by all HIV-1 subtypes. Also, mAb 2556 was the best in competition with HIV-1+ serum antibodies, which is an extremely important consideration for efficacy in the treatment of HIV patients. When radiolabeled with alpha-emitting radionuclide 213-Bismuth ((213)Bi) - (213)Bi-2556 efficiently and specifically killed ACH-2 human lymphocytes chronically infected with HIV-1, and HIV-1 infected human peripheral blood mononuclear cells (hPBMCs). The number of binding sites for (213)Bi-2556 on the surface of the infected cells was >10(6). The in vivo experiments were performed in two HIV-1 mouse models--splenic and intraperitoneal. In both models, the decrease in HIV-1 infected hPBMCs from the spleens and peritoneum, respectively, was dose-dependent with the most pronounced killing of hPBMCs observed in the 100 µCi (213)Bi-2556 group (P = 0.01). Measurement of the blood platelet counts and gross pathology of the treated mice demonstrated the lack of toxicity for (213)Bi-2556.We describe the preclinical development of a novel radiolabeled mAb reagent that could potentially be part of an HIV eradication strategy that is ready for translation into the clinic as the next step in its development. As viral antigens are very different from "self" human antigens - this approach promises high selectivity, increased efficacy and low toxicity, especially in comparison to immunotoxins